Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
Key Highlights
- ➤33% of nearly 300 surveyed GLP-1 users preferred a hypothetical one-time procedure
- ➤84% selected a one-time procedure as their most valued feature
- ➤Revita retained approximately 80% of GLP-1-induced weight loss at six months
- ➤Fractyl expects REMAIN-1 12-month topline results in the first quarter of 2027
- ➤Approximately one million U.S. patients monthly face weight regain after GLP-1 discontinuation
Expert Statements
Pichamol Jirapinyo, Assistant Professor of Medicine at Harvard Medical School and Director of the Bariatric Endoscopy Fellowship at Brigham and Women’s Hospital
“Many patients discontinue GLP-1 therapy due to cost, insurance coverage, side effects, or concerns about long-term medication use. However, growing evidence shows that most patients experience weight gain after discontinuation”
Pichamol Jirapinyo, Assistant Professor of Medicine at Harvard Medical School and Director of the Bariatric Endoscopy Fellowship at Brigham and Women’s Hospital
“In clinical practice, we are seeing increasing numbers of patients seeking minimally invasive treatment options that could help them discontinue GLP-1 therapy while maintaining their weight loss. There is a substantial unmet need for safe, effective, and durable weight management solutions. A scalable, single-session outpatient procedure that could help patients maintain or achieve additional weight loss after GLP-1 discontinuation would represent a meaningful advancement in obesity care.”
Harith Rajagopalan, Co-Founder and Chief Executive Officer of Fractyl Health
“In addition to the large number of patients already discontinuing GLP-1s who are at immediate risk of weight regain, our research shows that 1 out of 3 patients who are still currently on a GLP-1 would choose a one-time procedural therapy over ongoing medication”
Harith Rajagopalan, Co-Founder and Chief Executive Officer of Fractyl Health
“This research reinforces our belief that there is meaningful patient interest in a procedural approach to weight maintenance. Together with the encouraging six-month results from REMAIN-1, these findings strengthen our confidence in Revita’s potential to address this need and are helping inform our preparations for future commercialization.”
* Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain * One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication * A one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy. The findings reinforce the potentially substantial commercial opportunity for investigational Revita and help inform the Company’s ongoing commercial planning.
Get started
Create a free account to read the full story.